BR0011369A - Método de detecção precoce de uma infecção flaviviral, kit de diagnóstico precoce, processo de purificação da protéina ns1 de um flavivìrus composição imunogese, utilização da proteìna ns1, de pelo menos um anticorpo monoclonal anti-ns1, e, processo de expressão de um polinucleotìdeo codificado para a proteìna ns1 de um vìrus da dengue - Google Patents

Método de detecção precoce de uma infecção flaviviral, kit de diagnóstico precoce, processo de purificação da protéina ns1 de um flavivìrus composição imunogese, utilização da proteìna ns1, de pelo menos um anticorpo monoclonal anti-ns1, e, processo de expressão de um polinucleotìdeo codificado para a proteìna ns1 de um vìrus da dengue

Info

Publication number
BR0011369A
BR0011369A BR0011369-7A BR0011369A BR0011369A BR 0011369 A BR0011369 A BR 0011369A BR 0011369 A BR0011369 A BR 0011369A BR 0011369 A BR0011369 A BR 0011369A
Authority
BR
Brazil
Prior art keywords
protein
flavivirus
detection method
early
dengue virus
Prior art date
Application number
BR0011369-7A
Other languages
English (en)
Other versions
BRPI0011369B1 (pt
BRPI0011369B8 (pt
Inventor
Marie Flamand
Francoise Megret
Sophie Alcon
Antoine Talarmin
Philippe Despres
Vicente Deubel
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9907290A external-priority patent/FR2794864A1/fr
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of BR0011369A publication Critical patent/BR0011369A/pt
Publication of BRPI0011369B1 publication Critical patent/BRPI0011369B1/pt
Publication of BRPI0011369B8 publication Critical patent/BRPI0011369B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODO DE DETECçãO PRECOCE DE UMA INFECçãO FLAVIVIRAL, KIT DE DIAGNóSTICO PRECOCE, PROCESSO DE PURIFICAçãO DA PROTEìNA NS1 DE UM FLAVIVìRUS, COMPOSIçãO IMUNOGENE, UTILIZAçãO DA PROTEìNA NS1, DE PELO MENOS UM ANTICORPO MONOCLONAL ANTI-NS1, E, PROCESSO DE EXPRESSãO DE UM POLINUCLEOTìDEO CODIFICANDO PARA A PROTEìNA NS1 DE UM VìRUS DA DENGUE". Método de detecção precoce de uma infecção flaviviral compreendendo a detecção da glicoproteína não estrutural NS1 de um flavivírus em uma amostra biológica, durante a fase clínica da infecção, por um método imunológico empregando pelo menos dois anticorpos idênticos ou diferentes, o primeiro anticorpo sendo constituído por anticorpos policlonais ou monoclonais previamente selecionados para sua afinidade elevada para a referida proteína NS1 de forma hexamérica.
BRPI0011369A 1999-06-09 2000-06-09 método de detecção precoce e kit de diagnóstico precoce de uma infecção flaviviral, processo de purificação da proteína ns1 de um flavivírus,composição imunogênca,utilização da proteína ns1,de pelo menos um anticorpo monoclonal anti-ns1 e da proteína ns1 de forma hexamérica,e, processo de expressão de um polinucleotídeo codificado para a proteína ns1 de um vírus da dengue BRPI0011369B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR99/07290 1999-06-09
FR9907290A FR2794864A1 (fr) 1999-06-09 1999-06-09 Methode de detection precoce des flavivirus et ses applications
FR9907361A FR2794865B1 (fr) 1999-06-09 1999-06-10 Methode de detection precoce des flavivirus et ses applications
FR99/07361 1999-06-10
PCT/FR2000/001620 WO2000075665A1 (fr) 1999-06-09 2000-06-09 Detection precoce des flavivirus en utilisant la clycoproteine ns1

Publications (3)

Publication Number Publication Date
BR0011369A true BR0011369A (pt) 2003-08-12
BRPI0011369B1 BRPI0011369B1 (pt) 2019-03-19
BRPI0011369B8 BRPI0011369B8 (pt) 2021-05-25

Family

ID=26234982

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011369A BRPI0011369B8 (pt) 1999-06-09 2000-06-09 método de detecção precoce e kit de diagnóstico precoce de uma infecção flaviviral, processo de purificação da proteína ns1 de um flavivírus,composição imunogênca,utilização da proteína ns1,de pelo menos um anticorpo monoclonal anti-ns1 e da proteína ns1 de forma hexamérica,e, processo de expressão de um polinucleotídeo codificado para a proteína ns1 de um vírus da dengue

Country Status (15)

Country Link
US (5) US6870032B1 (pt)
EP (1) EP1190257B1 (pt)
JP (1) JP4625215B2 (pt)
KR (1) KR20020042533A (pt)
CN (1) CN1360678B (pt)
AT (1) ATE274701T1 (pt)
AU (1) AU776844B2 (pt)
BR (1) BRPI0011369B8 (pt)
DE (1) DE60013287T2 (pt)
ES (1) ES2226894T3 (pt)
FR (1) FR2794865B1 (pt)
HK (1) HK1045729B (pt)
MX (1) MXPA01012662A (pt)
PT (1) PT1190257E (pt)
WO (1) WO2000075665A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
US20060204523A1 (en) * 2001-11-26 2006-09-14 Khromykh Alexander A Flavivirus vaccine delivery system
US7473424B2 (en) * 2003-01-31 2009-01-06 The Scripps Research Institute Anti-dengue virus antibodies and compositions
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
EP1664786B1 (en) 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
JP4813471B2 (ja) * 2004-06-18 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ハンタウイルス感染の診断のための方法および試薬
FR2871888A1 (fr) * 2004-06-22 2005-12-23 Pasteur Institut Methode de diagnostic ou de depistage d'une infection clinique ou asymptomatique par un flavivirus du groupe encephalitique
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US20070211241A1 (en) * 2006-02-24 2007-09-13 Noriyuki Aizawa Optical defect inspection apparatus
US7629117B2 (en) * 2006-06-20 2009-12-08 Mahidol University Determination of risk of developing dengue hemorrhagic fever/dengue shock syndrome, methods and compositions therefor
EP2078201A2 (en) * 2006-10-05 2009-07-15 Agency for Science, Technology and Research Dengue diagnosis and treatment
CN101226196B (zh) * 2008-02-02 2012-05-09 南方医科大学 一种检测ⅱ型登革病毒ns1抗原的免疫诊断试剂盒
US20090275499A1 (en) * 2008-02-29 2009-11-05 Marie Flamand Nonstructural protein ns1 as a novel therapeutic target against flaviviruses
CN101551393B (zh) * 2009-04-02 2012-09-19 南方医科大学 一种检测ⅳ型登革病毒ns1抗原的免疫诊断试剂盒
US8920804B2 (en) 2011-12-22 2014-12-30 Inbios International, Inc. Methods and materials for the detection of dengue virus infection
US10046045B2 (en) 2013-12-20 2018-08-14 The Regents Of The University Of Michigan Vaccine compositions and uses thereof
FR3017713B1 (fr) * 2014-02-18 2018-01-12 Biomerieux Procede et kit pour determiner la probabilite pour un patient d'evoluer vers une dengue severe
FR3017714A1 (fr) * 2014-02-18 2015-08-21 Biomerieux Sa Procede et kit pour determiner la probabilite pour un patient d'evoluer vers une dengue severe
DE102014205098B4 (de) 2014-03-19 2016-02-04 Universität Leipzig Verfahren und Verwendungen von Mitteln zum Nachweis einer Denguevirus-Infektion
CN105445458A (zh) * 2015-11-13 2016-03-30 山东省滨州畜牧兽医研究院 鉴别鸭坦布苏病毒感染动物和灭活苗免疫动物的elisa检测试剂盒
MX2018009738A (es) 2016-02-11 2019-02-07 Massachusetts Inst Technology Anticuerpos monoclonales de proteína ns1 anti-virus del dengue.
EP3420357B1 (en) 2016-02-22 2023-12-20 Euroimmun Medizinische Labordiagnostika AG An immunoassay for the diagnosis of zika viral infection
CN110709410A (zh) * 2017-04-26 2020-01-17 豪夫迈·罗氏有限公司 可溶性和免疫反应性寨卡病毒ns1多肽
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
KR102218517B1 (ko) * 2019-01-23 2021-02-19 충북대학교 산학협력단 단일클론항체 쌍을 이용한 지카 바이러스의 검출 방법
KR102218561B1 (ko) * 2019-01-28 2021-02-19 충북대학교 산학협력단 단일클론항체 쌍을 이용한 뎅기 바이러스의 검출 방법
WO2021058809A1 (en) 2019-09-25 2021-04-01 Institut Pasteur A novel complex formed between the flaviviral non-structural ns1 protein and plasma lipoproteins
CN113355344B (zh) * 2021-08-10 2021-11-02 北京溯本源和生物科技有限公司 一种流感病毒ns1蛋白的表达质粒、重组蛋白和特异性单克隆抗体及应用
CN113621058B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 黄热病毒抗体及其应用
CN113683690B (zh) * 2021-08-19 2023-05-23 中国科学院微生物研究所 针对黄热病毒ns1蛋白的抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR10904E (fr) 1909-11-09 David Rojat Filtre réalisant dans le meme appareil la stérilisation par les rayons ultra-violets et la filtration, applicable aux liquides
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FI902814A0 (fi) * 1989-06-06 1990-06-05 Immuno Ag Proteiner, vaccin och nukleinsyror.
GB9209243D0 (en) * 1992-04-29 1992-06-17 Univ Singapore Dengue virus
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications

Also Published As

Publication number Publication date
HK1045729A1 (en) 2002-12-06
KR20020042533A (ko) 2002-06-05
US7282341B2 (en) 2007-10-16
AU6447400A (en) 2000-12-28
FR2794865B1 (fr) 2003-04-18
CN1360678A (zh) 2002-07-24
US6870032B1 (en) 2005-03-22
DE60013287D1 (de) 2004-09-30
WO2000075665A1 (fr) 2000-12-14
US8709427B2 (en) 2014-04-29
US20090068213A1 (en) 2009-03-12
US20120009216A1 (en) 2012-01-12
ATE274701T1 (de) 2004-09-15
FR2794865A1 (fr) 2000-12-15
BRPI0011369B1 (pt) 2019-03-19
EP1190257B1 (fr) 2004-08-25
PT1190257E (pt) 2004-12-31
JP2003501661A (ja) 2003-01-14
EP1190257A1 (fr) 2002-03-27
US20050186562A1 (en) 2005-08-25
US7670766B2 (en) 2010-03-02
JP4625215B2 (ja) 2011-02-02
MXPA01012662A (es) 2004-03-19
US20090226478A1 (en) 2009-09-10
DE60013287T2 (de) 2005-09-15
AU776844B2 (en) 2004-09-23
HK1045729B (zh) 2005-03-18
BRPI0011369B8 (pt) 2021-05-25
ES2226894T3 (es) 2005-04-01
CN1360678B (zh) 2013-07-03

Similar Documents

Publication Publication Date Title
BR0011369A (pt) Método de detecção precoce de uma infecção flaviviral, kit de diagnóstico precoce, processo de purificação da protéina ns1 de um flavivìrus composição imunogese, utilização da proteìna ns1, de pelo menos um anticorpo monoclonal anti-ns1, e, processo de expressão de um polinucleotìdeo codificado para a proteìna ns1 de um vìrus da dengue
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
BR9916020A (pt) Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
DE69434117T2 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
ATE389020T1 (de) Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
FI902143A0 (fi) Hiv-peptider, artificiella hiv -antigener och immunobestaemningsfoerpackningar.
BRPI0111731C1 (pt) suporte sólido de imunoensaio, métodos de detecção de infecção pelo vírus da hepatite c (hcv) em uma amostra biológica, e de produção de um suporte sólido de imunoensaio, e, kit de teste de imunodiagnóstico
BR9712298A (pt) Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão
ATE349533T1 (de) Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
DE69834719D1 (de) Methode zur diagnose von abnormalem knochenstoffwechsel
DE10082504D2 (de) Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay
DE60138192D1 (de) Verfahren zur quantifizierung der akt-protein-expression
AU2002356520A1 (en) Detection of bovine viral diarrhea virus in tissue samples
ATE256704T1 (de) Antikörper und diagnostizierverfahren zur pestivirusdiagnose
DE69327167D1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
SE8901566D0 (sv) Nya peptider inkluderande en disulfidbindning
RU2001128868A (ru) Способ диагностики наружного генитального эндометриоза
TH160012A (th) การพัฒนาและการผลิตชุดการตรวจวินิจฉัยโรคไวรัสตับอักเสบชนิดซี
TH68307B (th) การพัฒนาและการผลิตชุดการตรวจวินิจฉัยโรคไวรัสตับอักเสบชนิดซี
ITMI991451A1 (it) Unh sistema diagnostico per il rilevamento di anticorpi specifici anti-hgv con l'uso complementare di due peptidi sintetici del virus dell'e

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2515 DE 19/03/2019.QUANTO AO ITEM (54) TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2541 DE 17/09/2019,QUANTO AO ITEM (54) TITULO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/06/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/06/2020